NCT02688036CompletedPhase 3
Hypofractionated vs. Conventionally Fractionated Concurrent CRT for LD-SCLC
Phase III Randomized Study of Hypofractionated vs Conventionally Fractionated Concurrent Chemo-radiotherapy for Limited Disease Small Cell Lung Cancer
Source: ClinicalTrials.gov · Last updated 29 May 2026
Brief summary (registry, in English)
The purpose of this study is to determine whether hypofractionated concurrent chemo-radiotherapy has the same efficiency as conventionally fractionated concurrent chemo-radiotherapy in Limited Disease Small Cell Lung Cancer.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 860 (estimated)
- First submitted
- 20 Nov 2015
- Start date
- Feb 2016
- Primary completion date
- Oct 2022
- Lead sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Diseases
- Lung cancer
- NCT number
- NCT02688036
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 860
- From Feb 2016 to the primary completion date, Oct 2022
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Oral or intravenous use of steroids
Other illness
- Malignant tumors of other sites. Non melanoma skin cancer and Cervical carcinoma in situ were not included if curable.
- Active heart disease or acute myocardial infarction happen in six months.
- Psychiatric history.
- Uncontrolled diabetes or hypertension
- Acute bacterial or fungal infection
Other
- Pregnant woman or woman need to breast feed or woman with positive chorionic gonadotrophin (HCG)
- Interstitial pneumonia or Active pulmonary fibrosis
Who the study is looking for
- 18\~70 years old, ECOG 0-2
- patients with histologically or cytologically proved small cell lung cancer
- Limited disease (LD), was characterized by tumors confined to one hemithorax. It may include ipsilateral hilar, both mediastinum and both supraclavicular nodes. Metastatic lymph nodes were defined as lymph nodes with short diameter of more than 1cm or FDG uptake in PET. The thickness of pleural effusion was less than 1cm unless malignant pleural effusion was cytologically proved. In a word, stage I-IIIB excluding the patients with lung metastases should be defined as LD according to AJCC cancer staging 7th edition.
- No progression after 2 cycles of chemotherapy with EP.
- No prior history of anti-tumor treatment.
- No severe internal diseases and no organ dysfunction
- Written informed consent provided and
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Cancer Insititute and Hosiptal of Chinese Academy of Medical Sciences Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.